ArticleOncotarget2017

The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.

Zuquan Xiong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.